(Rac) -BDA-366

• Description :

  (Rac) -BDA-366 (example 2) is the despinner of BDA-366 (HY-101083) . BDA-366 is a potent Bcl-2 antagonist (Ki=3.3 nM), binding Bcl-2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl-2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells[1][2].

• UNSPSC :

  12352005

• Target :

  Bcl-2 Family

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/rac-bda-366.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1C2=C(NCC3OC3)C=CC(NCC(O)CN(CC)CC)=C2C(C4=CC=CC=C41)=O

• Molecular Formula :

  C24H29N3O4

• Molecular Weight :

  423.50

• References & Citations :

  [1]Spinx Pharmaceuticals Corp. Preparation of bis (hydroxyalkylamino) anthraquinones as protein kinase C inhibitors. World Intellectual Property Organization, WO9207557 A1 1992-05-14|[2]Han B, Park D, Li R, et al. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 2015;27 (6) :852-863.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [142645-19-0]